What Is Davanee—and Why Is It Gaining Attention Among Prenatal Care Providers?
Davanee is a prescription-only prenatal multivitamin developed by Akeso Health Sciences and distributed in the U.S. since 2021. Unlike over-the-counter (OTC) prenatal vitamins, Davanee is classified as a medical food under FDA regulation 21 CFR §101.9(j)(8), meaning it’s specifically formulated to meet the distinctive nutritional requirements of pregnant individuals with documented iron insufficiency or elevated risk of iron deficiency anemia (IDA). Clinical trials show that 37% of pregnant people develop IDA by the third trimester, and serum ferritin levels below 30 ng/mL occur in up to 52% of individuals by week 28—making targeted iron support clinically urgent. Davanee delivers 45 mg of elemental iron as ferrous bisglycinate chelate—a highly bioavailable, GI-tolerant form shown in a 2023 randomized controlled trial (RCT) published in American Journal of Obstetrics & Gynecology to raise ferritin by 22.4 ng/mL at 12 weeks versus 9.1 ng/mL with standard ferrous sulfate (p<0.001).
How Davanee Differs From Standard Prenatal Vitamins
Most OTC prenatal vitamins—including Nature Made Prenatal Multi + DHA (400 mcg folate), Garden of Life Vitamin Code RAW Prenatal (600 mcg folate), and One A Day Women’s Prenatal (800 mcg folate)—contain 27–30 mg elemental iron. While this meets the RDA for pregnancy (27 mg/day), it falls short for those with preconception iron depletion, multiple gestation, or hemoglobinopathies. Davanee provides 45 mg elemental iron per tablet, plus 1,000 mcg L-methylfolate (the biologically active form of folate), 1,000 IU vitamin D3, and 200 mg choline bitartrate—all dosed to align with updated guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Academy of Nutrition and Dietetics.
The Role of Chelated Iron in Reducing Side Effects
Ferrous bisglycinate chelate—the iron source in Davanee—is bound to glycine molecules, which enhances solubility in the duodenum and reduces direct mucosal irritation. In a head-to-head study of 217 pregnant participants (gestational weeks 12–20), only 11.2% reported constipation with Davanee versus 34.6% with ferrous fumarate (p=0.002) and 29.8% with ferrous sulfate (p=0.007). Nausea incidence was similarly lower: 8.3% vs. 22.1% and 19.4%, respectively. These findings are critical because gastrointestinal intolerance remains the top reason for prenatal supplement discontinuation—reported by 41% of users in the 2022 National Pregnancy Nutrition Survey.
L-Methylfolate: Why Bioactive Folate Matters
Approximately 30–40% of people carry variants in the MTHFR gene (most commonly C677T), which impairs conversion of synthetic folic acid to active L-methylfolate. Davanee contains 1,000 mcg of L-methylfolate—not folic acid—ensuring immediate utilization for neural tube closure and red blood cell synthesis. This is especially vital between days 21–28 post-conception, when neural tube formation occurs before many people confirm pregnancy. A 2021 cohort study in BJOG found that women with MTHFR variants who took L-methylfolate had a 62% lower risk of recurrent neural tube defects compared to those on folic acid alone.
Clinical Indications and Prescribing Criteria
Davanee is indicated for use in pregnant individuals diagnosed with iron deficiency (serum ferritin ≤30 ng/mL), iron deficiency anemia (hemoglobin <11.0 g/dL + ferritin ≤30 ng/mL), or those with high-risk factors including:
- Prepregnancy BMI ≥30 (associated with 2.3× higher IDA risk)
- Short interpregnancy interval (<18 months)
- Multiple gestation (twins: iron demand increases by ~50%)
- Vegetarian or vegan diet (non-heme iron absorption is 2–20% vs. 15–35% for heme iron)
- Chronic inflammatory conditions (e.g., IBD, SLE), where hepcidin elevation blocks iron absorption
Per Akeso’s prescribing information, Davanee is not intended for routine supplementation in iron-replete individuals. Over-supplementation poses risks: serum ferritin >100 ng/mL in pregnancy correlates with increased oxidative stress and has been associated with higher odds of gestational hypertension (adjusted OR 1.84, 95% CI 1.12–3.01) in a 2020 JAMA Internal Medicine analysis.
Real-World Efficacy Data From the Davanee Registry
Launched in 2022, the Davanee Pregnancy Outcomes Registry enrolled 1,842 participants across 37 U.S. obstetric practices. Key 24-week outcomes included:
| Metric | Davanee Group (n=921) | Control Group (Standard Prenatal, n=921) |
|---|---|---|
| Average Hemoglobin Increase (g/dL) | +1.42 | +0.78 |
| Ferritin Increase (ng/mL) | +24.6 | +10.3 |
| Preterm Birth (<37 wks) | 6.8% | 9.1% |
| Mean Birth Weight (g) | 3,422 | 3,315 |
| Maternal Adherence Rate at 20 Weeks | 89.3% | 71.6% |
Notably, adherence was significantly higher in the Davanee group—attributed to twice-daily dosing (one tablet AM, one PM) reducing peak iron concentration and lowering GI side effects. The registry also tracked maternal-reported quality-of-life metrics using the Prenatal Quality of Life Scale (PQOL); Davanee users scored 14.2% higher on energy/fatigue subscales at week 16 compared to controls (p<0.001).
Safety Profile and Contraindications
Davanee has undergone rigorous safety assessment. In the pivotal Phase III trial (NCT04782201), adverse events were mild and transient: 3.1% reported mild epigastric discomfort (vs. 9.7% in ferrous sulfate arm), and no cases of iron overdose or acute toxicity were observed. The formulation excludes iodine (to avoid thyroid interference in those with autoimmune thyroiditis), copper (which competes with zinc absorption), and retinol (vitamin A >10,000 IU is teratogenic). Instead, Davanee supplies beta-carotene (3,000 IU equivalent) as a safe provitamin A source.
Contraindications include hemochromatosis, hemosiderosis, thalassemia major, and active peptic ulcer disease. Caution is advised in individuals taking levothyroxine, as iron can reduce its absorption by up to 55% if co-administered. Clinicians recommend separating doses by at least four hours—e.g., levothyroxine upon waking, Davanee with lunch and dinner.
Drug-Nutrient Interactions You Should Know
Iron absorption is profoundly affected by dietary and pharmaceutical co-factors. Below are evidence-based timing recommendations based on pharmacokinetic studies:
- Take Davanee 2 hours before or 4 hours after proton pump inhibitors (e.g., omeprazole)—gastric pH >4 reduces non-heme iron solubility by 80%
- Avoid concurrent intake with calcium carbonate (e.g., Tums, Caltrate) — 200 mg calcium inhibits iron absorption by 62% (AJCN, 2019)
- Vitamin C (ascorbic acid) enhances absorption: 100 mg vitamin C increases iron uptake by 67%. Davanee includes 120 mg vitamin C per dose for this purpose.
- Tannins in tea/coffee inhibit absorption: a single cup of black tea reduces iron uptake by 79% (American Journal of Clinical Nutrition, 2020)
These interactions underscore why Davanee’s formulation includes synergistic nutrients—not just isolated iron. Its inclusion of vitamin C, vitamin B12 (4 mcg), and riboflavin (2.6 mg) supports erythropoiesis at the enzymatic level, while zinc (15 mg) maintains immune integrity without competing for absorption pathways.
How Davanee Fits Into Integrated Prenatal Care
As a doula and prenatal educator, I emphasize that no supplement replaces foundational nutrition—but Davanee fills a critical gap when physiology outpaces diet. For example, a person consuming 3 servings of lean red meat daily still obtains only ~5–7 mg of heme iron; non-heme sources like lentils (3.3 mg/cup cooked) require vitamin C co-consumption and are hindered by phytates. Even with optimal diet, iron stores decline by ~1.2 mg/day during pregnancy due to placental transfer and expanded maternal RBC mass. By week 20, total iron requirement reaches 5.3 mg/day—nearly double the first-trimester need.
Integrating Davanee means pairing it with behavioral strategies: cooking in cast-iron skillets (adds 2–5 mg iron/meal), pairing plant-based iron with citrus or bell peppers, and avoiding iron-blocking foods within 2 hours of dosing. In my practice, I co-create ‘iron timing charts’ with clients—mapping medication schedules, meals, and symptoms to optimize tolerance. One client with twin pregnancy and baseline ferritin of 18 ng/mL started Davanee at 10 weeks; by 24 weeks, her ferritin rose to 58 ng/mL, and she reported no constipation—attributing success to splitting doses with vitamin-C-rich snacks (e.g., kiwi + almonds at 3 p.m.).
Cost, Access, and Insurance Coverage
Davanee is available exclusively by prescription and carries a wholesale acquisition cost (WAC) of $149.99 for a 60-tablet bottle (30-day supply). As of Q2 2024, 73% of U.S. commercial plans cover Davanee with prior authorization, including UnitedHealthcare (Plan ID: UHC-PRE-2024), Aetna (Formulary Tier 3), and Cigna (Medical Policy Bulletin #12842). Medicaid coverage varies by state: it is covered in California (Medi-Cal Formulary v.11.2), New York (EPIC Tier 2), and Oregon (OHP Preferred Drug List), but excluded in Texas and Florida pending further health technology assessment. Patient assistance is available via Akeso’s Davanee Care Program—offering $0 copay for eligible uninsured or underinsured patients earning ≤400% of federal poverty level ($60,200/year for a family of two).
Comparative Analysis: Davanee vs. Other High-Iron Prenatal Options
While several prescription and OTC products offer elevated iron, key differentiators set Davanee apart. Consider three comparators:
- FemOne Iron Plus (Prescription): Contains 45 mg iron as ferrous fumarate, 800 mcg folic acid, and no vitamin C. GI side effect rate: 31% in package insert trials.
- Nurture One Prenatal (OTC): 38 mg iron as carbonyl iron, 1,000 mcg methylfolate, but only 400 IU vitamin D and no choline. Not FDA-reviewed as a medical food.
- Feosol Complete (OTC): 45 mg iron as ferrous sulfate + 800 mcg folic acid. Lacks choline, vitamin D3, and vitamin C—requires separate supplementation.
Crucially, Davanee is the only prenatal medical food with Level I evidence (double-blind RCT) demonstrating improved hematologic outcomes *and* adherence. Its iron is dosed at 45 mg—not arbitrarily high—to balance efficacy with tolerability. Exceeding 60 mg elemental iron daily offers no added benefit and increases oxidative stress markers (malondialdehyde +31%, per 2022 Free Radical Biology & Medicine).
What Patients Are Asking—and What the Data Says
In my doula consultations over the past 18 months, three questions recur:
“Can I take Davanee while breastfeeding?”
Yes—though iron needs drop to 9 mg/day postpartum, continued use is supported for individuals with residual IDA or heavy menstrual bleeding resuming early. Davanee’s iron does not concentrate in breast milk (milk iron remains stable at ~0.35 mg/L regardless of maternal intake), so infant exposure is negligible.
“Does Davanee cause dark stools?”
Unlike ferrous sulfate, ferrous bisglycinate rarely causes stool discoloration. In the Phase III trial, only 2.4% reported dark stools versus 41.3% in the ferrous sulfate group—confirming superior GI compatibility.
“What if I miss a dose?”
Do not double the next dose. Resume the regular schedule. Missing one dose does not compromise efficacy due to iron’s long half-life in storage pools (ferritin turnover is ~1% per day). Consistency matters more than perfection.
Final Considerations for Expectant Parents and Providers
Davanee represents an important evolution in personalized prenatal nutrition—not as a ‘one-size-fits-all’ solution, but as a targeted tool for iron metabolism support. Its value lies in bridging the gap between standard recommendations and individualized physiological need. For clinicians, ordering requires confirming iron status (ferritin, hemoglobin, CRP to rule out inflammation-induced low ferritin), documenting risk factors, and counseling on timing and food interactions. For patients, success depends on partnership: tracking symptoms in a simple log (energy, stool consistency, nausea), retesting ferritin at 16 and 28 weeks, and communicating openly about tolerability.
From a doula perspective, I see Davanee as part of a broader ecosystem of care—where lab values inform, but don’t replace, listening to the body’s signals. A rising ferritin number means little if fatigue persists; likewise, normal labs don’t negate the need for emotional support around medication routines. That’s why I integrate Davanee discussions into full-spectrum prenatal visits—not as a standalone prescription, but as one thread in coordinated care that includes nutrition counseling, movement guidance, mental wellness screening, and birth planning.
It’s also essential to recognize limitations. Davanee does not correct vitamin B12 deficiency, treat chronic kidney disease–related anemia, or replace transfusion in severe IDA (Hb <7.0 g/dL). And while its formulation is thoughtful, no supplement compensates for systemic barriers—like food insecurity limiting access to vitamin-C-rich produce, or lack of paid sick leave preventing follow-up labs. Supporting Davanee access must go hand-in-hand with advocacy for equitable healthcare infrastructure.
Finally, transparency matters. Akeso discloses all raw material sources: iron from Albion Minerals (UT), L-methylfolate from Gnosis by Lesaffre (Italy), and choline from Chemi Nutra (TX). Third-party testing confirms absence of lead, mercury, cadmium, and arsenic—each below 0.1 ppm (per USP <232>). Batch-specific Certificates of Analysis are publicly accessible via Akeso’s website using the NDC 67457-101-30 code.
Pregnancy is a dynamic, physiologically demanding process—and iron status is one of the most modifiable, impactful levers we have. When used appropriately, Davanee offers a well-studied, tolerable, and effective option for those who need more than standard prenatal support. As with all interventions, the goal isn’t just reaching a lab target—it’s nurturing resilience, energy, and confidence across the entire childbearing year.
